Opsana Therapeutics (Ireland) a preclinical-stage small molecule company focused on autoimmune and inflammatory disease through toll-like receptor modulators closed a $22.9M Series B financing. Participants include Novartis Venture Funds, Fountain Healthcare Partners, Inventages Venture Capital and Seroba Kernel Life Sciences.